Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00624195 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of CNS-targeted HAART (CIT2)
A Phase 2 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT00624195 is a Phase 2 study that has completed, run by University of California, San Diego. The registered enrollment target is 59 participants.
The verdict
NCT00624195, a Phase 2 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
CIT2 is a strategy for targeting HAART (Highly Active Antiretroviral Therapy) to the CNS (Central Nervous System) in patients with HIV associated neurocognitive impairment (HNCI). The primary goal of this study is to evaluate the effectiveness of CNS-targeted (CNS-T) as compared to non-CNS-targeted (non-CNS-T) HAART in treating HNCI globally and in different domains of functioning known to be affected by HIV. It is hypothesized that participants in the CNS-T arm will have greater improvement in neurocognitive functioning than those in the non-CNS-T arm. The secondary goal of the study is to compare participants assigned to CNS-T and non-CNS-T HAART on measures of CNS and systemic HIV suppression (undetectable CSF and plasma VL). It is also hypothesized that although CSF viral suppression will be more frequent in the CNS-T arm, plasma viral suppression will be similar in the two treatment arms.
Interventions
- DRUG FDA Approved Antiretroviral Therapy (see list below)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2007-03 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00624195
The ClinicalTrials.gov registry entry for NCT00624195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FDA Approved Antiretroviral Therapy (see list below) is the first listed.
NCT00624195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00624195 about?
NCT00624195 is a clinical study titled "Clinical Trial of CNS-targeted HAART (CIT2)". CIT2 is a strategy for targeting HAART (Highly Active Antiretroviral Therapy) to the CNS (Central Nervous System) in patients with HIV associated neurocognitive impairment (HNCI). The primary goal of this study is to evaluate the effectiveness of CNS-targeted (CNS-T) as compared to non-CNS-targeted...
What is the current status of trial NCT00624195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2007-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00624195?
The interventions under investigation include: FDA Approved Antiretroviral Therapy (see list below) (DRUG).
Who is sponsoring clinical trial NCT00624195?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.